Approval · Notice of Compliance 506 · 2002
NEUPOGEN: Notice of Compliance 506
Issued June 19, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 506
- Date
- June 19, 2002
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Granulocyte colony stimulating factor, haematopoietic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NEUPOGEN | 01968017 | Marketed |
Medicinal ingredients
- FILGRASTIM (R-METHUG-CSF) 300 MCG per ML